Loading...

VTRS - Viatris Inc.

Analyst Downgrade Signal for 05-10-2022
Analyst Downgrade Signal: VTRS from Neutral to Underweight by Piper Sandler
Price Target: $10


Loading Chart VTRS

Stock Signal Information


Signal

Analyst Downgrade Signal: VTRS from Neutral to Underweight by Piper Sandler
Price Target: $10
Report Date: 05-10-2022
Symbol: VTRS - Viatris Inc.
Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Analyst Downgrade Signal: VTRS from Neutral to Underweight by Piper Sandler
Price Target: $10

  VTRS Technical Analysis

Company Contact

Viatris Inc. (VTRS)
1000 Mylan Boulevard
Canonsburg, PA 15317
Phone: 724 514 1968
Website: http://www.viatris.com
CEO: Mr. Robert J. Coury

VTRS, Viatris Inc.

VTRS Viatris Inc. Logo Image

NASDAQ, Nasdaq Global Select


Company Profile

Viatris Inc., a healthcare company, manufactures and distributes various medicines for patients in the United States and internationally. Its portfolio comprises approximately 1,400 approved molecules across a range of therapeutic areas, including non-communicable and infectious diseases; complex generic and branded medicines; a portfolio of biosimilars; and various over-the-counter consumer products, as well as active pharmaceutical ingredients. The company is headquartered in Canonsburg, Pennsylvania.